Ganne Sudha, Arora Surender, Karam Jocelyne, McFarlane Samy I
State University of New York, Division of Endocrinology, Diabetes and Hypertension, Downstate Medical Center, Brooklyn, NY, USA.
Expert Rev Cardiovasc Ther. 2007 Mar;5(2):201-11. doi: 10.1586/14779072.5.2.201.
Hypertension is a major component of the metabolic syndrome and a major cardiovascular risk factor. Both disorders are rapidly increasing in frequency, with hypertension affecting nearly 60 million Americans and over 1 billion people worldwide, and metabolic syndrome affecting 44% of the US population above the age of 60 years. Sedentary lifestyle, together with obesity and aging of the population, are the major contributing factors for this growing epidemic. Hypertension in metabolic syndrome possesses unique pathophysiological aspects that have considerable implications on therapy of this disease. In this article, we review the pathophysiology and provide a rationale for the current therapeutic options in light of the most recent clinical trials in the field.
